Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2006-10-31
To evaluate the safety and efficacy of MNTX in participants who have undergone segmental
colectomy and to assess if the time between the end of surgery and the first bowel movement
is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo
regimen.
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Completed
Bausch Health Americas, Inc.
Phase 3
2006-10-31
To evaluate the safety and efficacy of MNTX in participants who have undergone segmental
colectomy and to assess if the time between the end of surgery and the first bowel movement
is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo
regimen.
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Completed
Valeant Pharmaceuticals International, Inc.
Phase 3
2006-10-31
To evaluate the safety and efficacy of MNTX in participants who have undergone segmental
colectomy and to assess if the time between the end of surgery and the first bowel movement
is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo
regimen.
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
Completed
Progenics Pharmaceuticals, Inc.
Phase 2
2007-10-01
The primary purpose of this study is to evaluate the safety and dose-response relationship of
N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects
with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel
dysfunction (OIBD).
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
Completed
Bausch Health Americas, Inc.
Phase 2
2007-10-01
The primary purpose of this study is to evaluate the safety and dose-response relationship of
N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects
with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel
dysfunction (OIBD).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
